Immune System Phenomena

26 trials 16 recruiting

Filter these 26 trials by phase, country and sponsor.

Open in Search →

Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial Pending

2025-522376-82-00 allergic diseases (allergic rhinosinusitis, allergic as 5
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Recruiting

2025-523579-47-00 moderate to severe rheumatoid arthritis (RA) 4 2026-06-19
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or… Recruiting

2025-521034-28-00 Moderate to Severe Rheumatoid Arthritis (RA) 4 2025-12-05
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Pat… Recruiting

2023-507536-21-00 Advanced Solid Tumors 7 2024-10-04
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus w… Recruiting

2024-519930-22-00 Systemic Lupus Erythematosus (SLE) With or Without Acti 4 2026-05-18
Developing a first-void urine-based infection model to assess HPV virion infectivity after vaccination. Recruiting

2025-522053-18-00 Human Papillomavirus infection 4 2026-03-25
Pharmacokinetics, safety, and efficacy of fisetin - A phase I and pilot phase IIa study Recruiting

2023-506284-34-00 Healthy 9 2026-03-24
BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to suppo… Recruiting

2023-508116-32-00 Antibody-mediated rejection of renal grafts 4 2026-03-17
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish … Recruiting

2025-520655-92-00 No medical condition, prophylactic vaccine against deng 6 2025-09-11
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Prednisone treatment in acute interstitial nephritis (PRAISE) Recruiting

2024-520299-86-00 Acute interstitial nephritis 6 2025-01-22
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting

2023-504022-19-01 Polymyositis or dermatomyositis according to 2017 EULAR 5 2024-12-13
CITAR - Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids… Recruiting

2022-501130-33-00 Patients with histologically (or via cytology) confirme 4 2023-10-11
Pneumococcal vaccine response in lymph nodes Recruiting

2022-501519-15-00 Healthy volunteers 4 2023-04-01
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 4 2025-05-26
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction and Maintenance Therapy in Participants with Moderately to Severel… Ended

2024-513014-35-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2024-11-13
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
Effect of nucleoside reverse transcriptase inhibitors on innate immune priming Ended

2023-510378-14-00 modulation of the innate immune system in healthy subje 3 2024-06-20
Is dermal measles-mumps-rubella-vaccine administration better than regular injection? Ended

2023-503845-79-01 Measles, mumps, and rubella 4 2024-11-24
Using live vaccines to induce beneficial innate immune training and reduce systemic inflammation in COPD patients Ended

2023-504519-34-01 Chronic obstructive pulmonary disease 4 2024-02-22